Thalidomide in multiple myeloma: Current status and future prospects

被引:57
作者
Cavenagh, JD [1 ]
Oakervee, H [1 ]
机构
[1] St Bartholomews & Royal London Sch Med & Dent, London, England
关键词
multiple myeloma; thalidomide; clinical management; thrombosis; neuropathy;
D O I
10.1046/j.1365-2141.2003.03902.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
[1]  
Badros A, 2000, BLOOD, V96, p285B
[2]   Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].
Barlogie, B ;
Desikan, R ;
Eddlemon, P ;
Spencer, T ;
Zeldis, J ;
Munshi, N ;
Badros, A ;
Zangari, M ;
Anaissie, E ;
Epstein, J ;
Shaughnessy, J ;
Ayers, D ;
Spoon, D ;
Tricot, G .
BLOOD, 2001, 98 (02) :492-494
[3]   Thalidomide in the management of multiple myeloma [J].
Barlogie, B ;
Zangari, M ;
Spencer, T ;
Fassas, A ;
Anaissie, E ;
Badros, A ;
Cromer, J ;
Tricot, G .
SEMINARS IN HEMATOLOGY, 2001, 38 (03) :250-259
[4]  
Bellamy WT, 1999, CANCER RES, V59, P728
[5]  
Bennett CL, 2001, BLOOD, V98, p863A
[6]   The phenomenon known as acquired activated protein C resistance [J].
Clark, P ;
Walker, ID .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :767-773
[7]  
Corral LG, 1999, J IMMUNOL, V163, P380
[8]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[9]   Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].
Davies, FE ;
Raje, N ;
Hideshima, T ;
Lentzsch, S ;
Young, G ;
Tai, YT ;
Lin, B ;
Podar, K ;
Gupta, D ;
Chauhan, D ;
Treon, SP ;
Richardson, PG ;
Schlossman, RL ;
Morgan, GJ ;
Muller, GW ;
Stirling, DI ;
Anderson, KC .
BLOOD, 2001, 98 (01) :210-216
[10]  
Dimopoulos M, 2001, BLOOD, V98, p164A